Literature DB >> 14554091

Gp120 stability on HIV-1 virions and Gag-Env pseudovirions is enhanced by an uncleaved Gag core.

Jason Hammonds1, Xuemin Chen, Lingmei Ding, Timothy Fouts, Anthony De Vico, Jan zur Megede, Susan Barnett, Paul Spearman.   

Abstract

Human immunodeficiency virus type-1 (HIV-1) particles incorporate a trimeric envelope complex (Env) made of gp120 (SU) and gp41 (TM) heterodimers. It has been previously established that soluble CD4 (sCD4) interaction leads to shedding of gp120 from viral particles, and that gp120 may also be easily lost from virions during incubation or particle purification procedures. In the design of HIV particle or pseudovirion-based HIV vaccines, it may be important to develop strategies to maximize the gp120 content of particles. We analyzed the gp120 retention of HIV-1 laboratory-adapted isolates and primary isolates following incubation with sCD4 and variations in temperature. NL4-3 shed gp120 readily in a temperature- and sCD4-dependent manner. Surprisingly, inactivation of the viral protease led to markedly reduced shedding of gp120. Gp120 shedding was shown to vary markedly between HIV-1 strains, and was not strictly determined by whether the isolate was adapted to growth on immortalized T cell lines or was a primary isolate. Pseudovirions produced by expression of codon-optimized gag and env genes also demonstrated enhanced gp120 retention when an immature core structure was maintained. Pseudovirions of optimal stability were produced through a combination of an immature Gag protein core and a primary isolate Env. These results support the feasibility of utilizing pseudovirion particles as immunogens for the induction of humoral responses directed against native envelope structures.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14554091     DOI: 10.1016/s0042-6822(03)00467-7

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  25 in total

1.  Pseudovirion particles bearing native HIV envelope trimers facilitate a novel method for generating human neutralizing monoclonal antibodies against HIV.

Authors:  Mark D Hicar; Xuemin Chen; Bryan Briney; Jason Hammonds; Jaang-Jiun Wang; Spyros Kalams; Paul W Spearman; James E Crowe
Journal:  J Acquir Immune Defic Syndr       Date:  2010-07       Impact factor: 3.731

2.  Multi-Parameter Exploration of HIV-1 Virus-Like Particles as Neutralizing Antibody Immunogens in Guinea Pigs, Rabbits and Macaques.

Authors:  Tommy Tong; Ema T Crooks; Keiko Osawa; James E Robinson; Mary Barnes; Cristian Apetrei; James M Binley
Journal:  Virology       Date:  2014-05       Impact factor: 3.616

3.  HIV-1 R5 Macrophage-Tropic Envelope Glycoprotein Trimers Bind CD4 with High Affinity, while the CD4 Binding Site on Non-macrophage-tropic, T-Tropic R5 Envelopes Is Occluded.

Authors:  Briana Quitadamo; Paul J Peters; Alexander Repik; Olivia O'Connell; Zhongming Mou; Matthew Koch; Mohan Somasundaran; Robin Brody; Katherine Luzuriaga; Aaron Wallace; Shixia Wang; Shan Lu; Sean McCauley; Jeremy Luban; Maria Duenas-Decamp; Maria Paz Gonzalez-Perez; Paul R Clapham
Journal:  J Virol       Date:  2018-01-02       Impact factor: 5.103

4.  The lipid membrane of HIV-1 stabilizes the viral envelope glycoproteins and modulates their sensitivity to antibody neutralization.

Authors:  Hamid Salimi; Jacklyn Johnson; Manuel G Flores; Michael S Zhang; Yunxia O'Malley; Jon C Houtman; Patrick M Schlievert; Hillel Haim
Journal:  J Biol Chem       Date:  2019-11-22       Impact factor: 5.157

5.  Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization.

Authors:  Jason Hammonds; Xuemin Chen; Timothy Fouts; Anthony DeVico; David Montefiori; Paul Spearman
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

Review 6.  The cytoplasmic tail of retroviral envelope glycoproteins.

Authors:  Philip R Tedbury; Eric O Freed
Journal:  Prog Mol Biol Transl Sci       Date:  2014-12-01       Impact factor: 3.622

7.  Role of the membrane-spanning domain of human immunodeficiency virus type 1 envelope glycoprotein in cell-cell fusion and virus infection.

Authors:  Liang Shang; Ling Yue; Eric Hunter
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

8.  Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies.

Authors:  Benjamin von Bredow; Juan F Arias; Lisa N Heyer; Brian Moldt; Khoa Le; James E Robinson; Susan Zolla-Pazner; Dennis R Burton; David T Evans
Journal:  J Virol       Date:  2016-06-10       Impact factor: 5.103

9.  A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120.

Authors:  Emma T Crooks; Penny L Moore; Michael Franti; Charmagne S Cayanan; Ping Zhu; Pengfei Jiang; Robbert P de Vries; Cheryl Wiley; Irina Zharkikh; Norbert Schülke; Kenneth H Roux; David C Montefiori; Dennis R Burton; James M Binley
Journal:  Virology       Date:  2007-06-19       Impact factor: 3.616

10.  A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge.

Authors:  Robert B Mandell; Ramesh Koukuntla; Laura J K Mogler; Andrea K Carzoli; Alexander N Freiberg; Michael R Holbrook; Brian K Martin; William R Staplin; Nicholas N Vahanian; Charles J Link; Ramon Flick
Journal:  Virology       Date:  2009-11-24       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.